L-2-Hydroxyglutarate and Metabolic Remodeling in Hypoxia
L-2-羟基戊二酸和缺氧中的代谢重塑
基本信息
- 批准号:10521282
- 负责人:
- 金额:$ 69.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-20 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:6-Phosphofructo-2-kinaseAddressAdverse effectsBackBiochemicalBrain Hypoxia-IschemiaBuffersCardiac MyocytesCardiovascular DiseasesCardiovascular systemCell HypoxiaCell physiologyCellsCitric Acid CycleCultured CellsCytoprotectionDataDependenceEchocardiographyEndothelial CellsEndotheliumEukaryotaFructose-2,6-bisphosphataseFunctional disorderG6PD geneGPX3 geneGenerationsGeneticGlucoseGlutathione DisulfideGlycolysisGoalsHeartHeterozygoteHomozygoteHumanHypoxiaIn VitroInjuryIschemiaKnock-outMass Spectrum AnalysisMeasuresMediatingMetabolicMetabolismMolecularMusMyocardialNADHNADPNADPH OxidaseOrganOxidasesOxidation-ReductionOxidoreductaseOxygenPentosephosphate PathwayPerfusionPhosphotransferasesPreparationProtein IsoformsReactionReactive Oxygen SpeciesReperfusion TherapyRoleSmall Interfering RNAStressTestingTimealpha ketoglutaratecancer cellcell injurycofactorcytotoxicityexperimental studyextracellularglutathione peroxidaseheart functionin vivoinhibitorinorganic phosphateinsightmetabolomicsmouse modelmyocardial hypoxianormoxianoveloverexpressionoxidationpharmacologicpreservationresponsesmall molecule
项目摘要
Project Summary. Adaptive metabolic responses to hypoxia reflect essential evolutionary survival
strategies in all eukaryotes. We recently identified a unique metabolite that increases in cardiovascular
(CV) cells in response to hypoxia, L-2-hydroxyglutarate (L2HG). This metabolite is derived from α-
ketoglutarate, or 2-oxoglutarate (2OG), a key intermediate in the tricarboxylic acid cycle. Once formed
from 2OG and NADH, L2HG has no other metabolic fate except to undergo oxidation back to 2OG by the
stereospecific dehydrogenase, L2HG dehydrogenase (L2HGDH), suggesting that it accommodates
(‘buffers’) the increase in reducing equivalents accompanying hypoxia. L2HG has two other unique
actions: it suppresses glycolysis and, as we show here, it increases pentose phosphate pathway (PPP)
activity. The central hypothesis of this proposal is that L2HG suppresses glycolysis and enhances PPP
activity in CV cells to eliminate reactive oxygen species (ROS), maintain cell redox potential, and preserve
cell function in hypoxia. To address this hypothesis, we will focus on three specific aims. First, we will
determine the molecular metabolic mechanisms underlying the effects of L2HG on glycolysis and PPP
activity. In particular, we will focus on the unique role of a specific phosphofructokinase-2 isoform,
PFKFB4, as a key regulatory determinant of increased flux through the PPP in hypoxia. Second, we will
determine the effect of this L2HG-induced increased PPP activity in hypoxia on cellular redox potential
and intra- and extracellular ROS elimination. Here, we will focus on PPP-derived NADPH and GSH as
key cofactors in NADPH oxidase and glutathione peroxidase activities, respectively, in order to enhance
elimination of excess ROS. Third, we will study the effects of L2HG in hypoxia or ischemia on cellular and
cardiac function, respectively, using unique cellular and genetic murine models. Taken together, these
studies should provide insights into the mechanisms by which L2HG promotes metabolic remodeling to
preserve cell and cardiac function in oxygen-limited states.
项目摘要。对缺氧的适应性代谢反应反映了基本的进化生存
所有真核生物的策略。我们最近发现了一种独特的代谢物,
(CV)细胞对缺氧的反应,L-2-羟基戊二酸(L2 HG)。该代谢产物来源于α-
酮戊二酸或2-酮戊二酸(2 OG),三羧酸循环中的关键中间体。一旦形成
从2 OG和NADH,L2 HG没有其他代谢的命运,除了经历氧化回到2 OG的
立体特异性脱氢酶,L2 HG脱氢酶(L2 HGDH),这表明它容纳
(“缓冲”)伴随缺氧的还原当量的增加。L2 HG还有两个独特的
作用:它抑制糖酵解,正如我们在这里显示的,它增加戊糖磷酸途径(PPP)
活动该建议的中心假设是L2 HG抑制糖酵解并增强PPP
活性,以消除活性氧(ROS),维持细胞氧化还原电位,并保护
细胞缺氧时的功能为了解决这一假设,我们将重点关注三个具体目标。一是
确定L2 HG对糖酵解和PPP影响的分子代谢机制
活动特别是,我们将集中在一个特定的磷酸果糖激酶-2亚型的独特作用,
PFKFB 4,作为缺氧时PPP通量增加的关键调节决定因素。二是
确定缺氧时L2 HG诱导的PPP活性增加对细胞氧化还原电位的影响
以及细胞内和细胞外ROS消除。在这里,我们将重点关注PPP衍生的NADPH和GSH,
NADPH氧化酶和谷胱甘肽过氧化物酶活性的关键辅因子,以增强
消除过量的ROS。第三,我们将研究L_2HG在缺氧或缺血状态下对细胞和神经元的影响。
心脏功能,分别使用独特的细胞和遗传小鼠模型。综上所述各项
研究应该提供深入了解L2 HG促进代谢重塑的机制,
在氧限制状态下保护细胞和心脏功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph Loscalzo其他文献
Joseph Loscalzo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph Loscalzo', 18)}}的其他基金
Branched-chain Keto-acids and Aerobic Glycolysis in Vascular Smooth Muscle Cells
血管平滑肌细胞中的支链酮酸和有氧糖酵解
- 批准号:
10731096 - 财政年份:2023
- 资助金额:
$ 69.01万 - 项目类别:
Center for Integrated Approached to Undiagnosed Diseases
未确诊疾病综合治疗中心
- 批准号:
10600194 - 财政年份:2022
- 资助金额:
$ 69.01万 - 项目类别:
L-2-Hydroxyglutarate and Metabolic Remodeling in Hypoxia
L-2-羟基戊二酸和缺氧中的代谢重塑
- 批准号:
10320786 - 财政年份:2020
- 资助金额:
$ 69.01万 - 项目类别:
L-2-Hydroxyglutarate and Metabolic Remodeling in Hypoxia
L-2-羟基戊二酸和缺氧中的代谢重塑
- 批准号:
10093718 - 财政年份:2020
- 资助金额:
$ 69.01万 - 项目类别:
Center for Integrated Approached to Undiagnosed Diseases
未确诊疾病综合治疗中心
- 批准号:
9788516 - 财政年份:2014
- 资助金额:
$ 69.01万 - 项目类别:
Center for Integrated Approached to Undiagnosed Diseases
未确诊疾病综合治疗中心
- 批准号:
10201702 - 财政年份:2014
- 资助金额:
$ 69.01万 - 项目类别:
Center for Integrated Approaches to Undiagnosed Diseases
未确诊疾病综合治疗中心
- 批准号:
8686403 - 财政年份:2014
- 资助金额:
$ 69.01万 - 项目类别:
Center for Integrated Approaches to Undiagnosed Diseases
未确诊疾病综合治疗中心
- 批准号:
9251865 - 财政年份:2014
- 资助金额:
$ 69.01万 - 项目类别:
Center for Integrated Approached to Undiagnosed Diseases
未确诊疾病综合治疗中心
- 批准号:
9593147 - 财政年份:2014
- 资助金额:
$ 69.01万 - 项目类别:
Center for Integrated Approaches to Undiagnosed Diseases
未确诊疾病综合治疗中心
- 批准号:
10696373 - 财政年份:2014
- 资助金额:
$ 69.01万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 69.01万 - 项目类别:
Research Grant














{{item.name}}会员




